Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(TSV: DMT )

N/A UNCHANGED
Last Price Updated: 3:59 PM EDT, Oct 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 0.1900 (5)
Ask (Size) 0.1900 (390)
Prev. Close 0.1500
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
From Cybin Inc.
Via Business Wire
Small Pharma Reports Fiscal Second Quarter 2024 Highlights
From Small Pharma Inc.
Via GlobeNewswire

Performance

More News

Read More
Small Pharma Obtains Final Order Approving Arrangement
From Cybin Inc.
Via Business Wire
Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
From Small Pharma Inc.
Via GlobeNewswire
Cybin to Acquire Small Pharma Inc.
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Cybin to Acquire Small Pharma Inc.
From Cybin Inc.
Via Business Wire
Small Pharma Reports Fiscal First Quarter 2024 Highlights
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma Announces SPL028 R&D Strategy Update
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma Announces Management Team Change
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma Announces Significant Developments In Intellectual Property Portfolio
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference
From Small Pharma Inc.
Via GlobeNewswire
First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25
From Small Pharma Inc.
Via GlobeNewswire
First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property
From Small Pharma Inc.
Via GlobeNewswire
First Patient Dosed in Small Pharma’s Drug Interaction Study
From Small Pharma Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.